2018
-
Gilead grabs Roche vet as CEO
Gilead Sciences has named Roche Holding's Daniel O’Day as its new chief executive.
12/10/2018 -
Roche wins key lung cancer combo approval
Roche Holding’s Tecentriq immunotherapy, in combination with Avastin and chemotherapy, won U.S. FDA approval as a first-line treatment for a type of lung cancer.
12/07/2018 -
Anti-pharma couple found dead
An elderly Pennsylvania couple, know for their personal crusade against McNeil Consumer Healthcare, was found dead outside their home.
12/07/2018 -
Tris Pharma recalls infant ibuprofen
Tris Pharma has voluntarily recalled three lots of Infants' Ibuprofen Concentrated Oral Suspension because the products have been found to potentially have higher concentrations of ibuprofen.
12/06/2018 -
Bayer stops trial of drug it hopes will be a blockbuster
Bayer has halted testing for vilaprisan, a new medication developed to treat uterine fibroids. The company said that it’s concerned about the risk of side effects uncovered in toxicology data.
12/05/2018 -
FDA gives Roche immunotherapy drug priority review
The FDA has awarded Roche an accelerated review of its immunotherapy drug, Tecentriq, to treat non small-cell lung cancer.
12/05/2018 -
FDA fast tracks Amgen myeloma treatment
The drugmaker's trial of its bispecific antibody for multiple myeloma found that seven out of ten patients given the second-highest dose of AMG420 responded to the drug
12/04/2018 -
Mylan recalls all batches of blood pressure drug in U.S.
The company recalled some batches two weeks ago but is now recalling 104 additional lots.
12/04/2018 -
Unilever nabs GSK nutrition business
After beating out potential bids from Nestle and Coca-Cola, Unilever has signed a deal to buy GlaxoSmithKline’s nutrition business, Horlicks, for $3.8 billion.
12/03/2018 -
Janssen affiliate and Dutch company ink $1.6B deal to develop cancer drug
Cilag, an affiliate of Janssen, is teaming up with a Netherlands-based biopharmac company called Argenx to develop a treatment for certain cancers.
12/03/2018 -
GSK bets big with Tesaro buy
GlaxoSmithKline has agreed to buy cancer biotech, Tesaro, for $5.1B.
12/03/2018 -
Annual Report: Cell, gene products with marketing authorization
ISCT publishes an annual report on global cell, gene therapy market authorization
11/30/2018 -
FDA warns about Sanofi MS drug
The FDA is warning consumers about the risk of rare but serious cases of stroke and tears in the lining of arteries in the head and neck associated with Sanofi’s multiple sclerosis drug, Lemtrada.
11/30/2018 -
Medicare changes could pain drugmakers
The latest proposal from the U.S. Centers for Medicare and Medicaid Services (CMS) may widen the circle of drugmakers who will be negatively affected.
11/30/2018 -
Bayer to lay off 12,000
Bayer will cut thousands of jobs as part of a corporate overhaul aimed towards winning back investor trust following its $63 billion takeover of Monsanto.
11/29/2018 -
Loxo, Bayer get first FDA win with $400k rare cancer drug
A cutting-edge oncology drug developed by Loxo Oncology and Bayer has won approval in the U.S.
11/29/2018 -
Pfizer scores six month extension for Lyrica patent
The FDA has handed a consolation prize to Pfizer, which is on the cusp of completely losing its patent on the company’s best-selling drug, Lyrica.
11/29/2018 -
Teva matches Mylan EpiPen generic price
The Israeli drugmaker is launching its generic EpiPen at the wholesale price of $300 for a pack of two auto-injectors
11/27/2018 -
Roche buys biotech company Jecure
The group's subsidiary Genentech will acquire Jecure Therapeutics, which is a biotech company based in the U.S. with novel drug discovery programs targeting serious inflammatory diseases
11/27/2018 -
Pfizer nabs fourth oncology approval in two months
The FDA has approved Pfizer’s new drug, Daurismo, for patients with acute myeloid leukemia.
11/26/2018